- Home
- SVIV vs ZNTL Comparison
SVIV vs ZNTL Comparison
Compare SVIV & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$3.76
Company Overview
Basic Information| Metric | SVIV | ZNTL |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.6M | 289.0M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SVIV | ZNTL |
|---|---|---|
| Price | $10.20 | $3.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 70.8K | ★ 975.7K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $1.13 |
| 52 Week High | $10.73 | $6.95 |
Technical Indicators
Market Signals| Indicator | SVIV | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 71.47 | 47.89 |
| Support Level | $9.93 | $3.75 |
| Resistance Level | $10.73 | $3.95 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 27.40 | 47.52 |
Price Performance
Historical Comparison SVIV
ZNTL
About SVIV Spring Valley Acquisition Corp. IV Class A Ordinary Shares
Spring Valley Acquisition Corp IV is a blank check company established for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.